MEI Pharma, Inc.
11455 El Camino Real, Suite 250
San Diego
California
92130
United States
Tel: (858) 369-7100
Website: https://www.meipharma.com/
Email: HR@meipharma.com
About MEI Pharma, Inc.
MEI Pharma is clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer.
MEI Pharma's portfolio of drug candidates includes multiple clinical-stage assets, including zandelisib, currently in ongoing clinical studies intended to support marketing applications with the U.S. Food and Drug Administration and other regulatory authorities globally. Each of MEI Pharma's pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors that we believe: (1) have the potential to be best-in-class, (2) address unmet medical needs and (3) deliver improved outcomes to patients either as standalone treatments or in combination with other therapeutic options. MEI is headquartered in San Diego, CA.
Stock Symbol:
MEIP
322 articles with MEI Pharma, Inc.
-
MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022
5/17/2022
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright Global Investment Conference 2022.
-
MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress
5/12/2022
MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced that two abstracts highlighting data and information for zandelisib, an investigational phosphatidylinositol 3-kinase delta inhibitor in clinical development for the treatment of B-cell malignancies, will be presented at the upcoming European Hematology Association 2022 Hybrid Congress to be held June 9 – 17, 2022.
-
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 02, 2022
5/2/2022
MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 100,000 shares of the company’s common stock to two new employees.
-
MEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022
4/8/2022
MEI Pharma, Inc. (NASDAQ: MEIP), today announced that two posters presenting preclinical data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 for zandelisib, an orally administered phosphatidylinositol-3-kinase (PI3K) inhibitor, and ME-344, a tumor selective mitochondrial inhibitor.
-
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2022
4/1/2022
MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 295,000 shares of the company’s common stock to four new employees.
-
The FDA recommends a randomized trial to adequately assess drug efficacy and safety of P13K inhibitor drug candidates.
-
MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA
3/24/2022
MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today provided an update after a recent meeting with the U.S. Food Drug Administration (FDA) to discuss the pursuit of a marketing authorization for zandelisib, a phosphatidylinositol-3-kinase (“PI3K”) inhibitor drug candidate, via the accelerated approval pathway under 21 CFR Part 314.500, Subpart H, based on data generated by the single arm Phase 2 TIDAL study.
-
MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
3/8/2022
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that two abstracts highlighting data from two oncology drug candidates in its pipeline will be presented at the upcoming American Association for Cancer Research Annual Meeting 2022 to be held April 8 – 13, 2022.
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Mar 01, 2022
3/1/2022
MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 210,000 shares of the company’s common stock to four new employees.
-
MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights
2/10/2022
MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, 2021, and highlighted recent corporate progress.
-
MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments
2/7/2022
MEI Pharma, Inc. today announced the expansion of its management team with the addition of two experienced industry executives.
-
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2/1/2022
MEI Pharma, Inc. today announced the grant of inducement stock options for an aggregate of 588,000 shares of the company’s common stock to seven new employees.
-
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2022
1/3/2022
MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 155,000 shares of the company’s common stock to seven new employees.
-
MEI Pharma Announces Closing of Public Offering of Common Stock - Dec 06, 2021
12/6/2021
MEI Pharma, Inc. announced that it has closed the previously announced underwritten public offering of 20,125,000 shares of its common stock, which includes 2,625,000 shares of common stock sold as a result of the full exercise by the underwriters of an option to purchase additional shares of common stock, at $2.60 per share for total gross proceeds, before underwriting commissions and estimated expenses, of approximately $52,325,000.
-
MEI Pharma Announced Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/3/2021
MEI Pharma, Inc. today announced the grant of inducement stock options for an aggregate of 166,000 shares of the company’s common stock to six new employees.
-
MEI Pharma Announces Pricing of Public Offering of Common Stock - Dec 02, 2021
12/2/2021
MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that it has priced the underwritten public offering of 17,500,000 shares of its common stock at $2.60 per share for total gross proceeds of $45,500,000.
-
MEI Pharma Announces Proposed Public Offering of Common Stock - Nov 30, 2021
11/30/2021
MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that it plans to offer 17,500,000 shares of its common stock in an underwritten public offering.
-
MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma
11/30/2021
MEI Pharma, Inc. today announced that the pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma.
-
MEI Pharma to Host Webcast on November 30, 2021 at 8:00 a.m. ET Reporting Data from Ongoing Global Phase 2 TIDAL Study of Zandelisib in Patients with Follicular Lymphoma
11/29/2021
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the company will host a live investor and analyst webcast on Tuesday, November 30, 2021 reporting on data from the ongoing global Phase 2 TIDAL study evaluating zandelisib in patients with relapsed or refractory follicular lymphoma.
-
MEI Pharma Appoints Biotechnology Executive Sujay Kango to its Board of Directors
11/23/2021
MEI Pharma, Inc. today announced the appointment of Mr. Sujay Kango to its board of directors effective November 22, 2021.